Business
Liminatus Pharma raises USD 4m in best-efforts public offering
Cerritos, California-based Liminatus Pharma (NASDAQ: LIMN) announced the pricing of a best-efforts public offering expected to generate approximately USD...
Innovent and Lilly's $8.5B Oncology Deal Sparks Global Cancer Research Collaboration
Innovent and Lilly Forge Strategic Alliance to Advance Global Oncology and Immunology Research
Gilgamesh Pharma Raises USD 60M Series A to Advance Neuropsychiatric Drug Pipeline
Gilgamesh Pharma, a clinical-stage neuroscience company headquartered in New York, has closed an oversubscribed USD 60 million Series A financing round to...
Artelo Biosciences raises USD 11m in private placement
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company based in Solana Beach, California, announced an Artelo $11 million private...
Excalipoint Therapeutics Closes Oversubscribed $68.7 Million Seed Round for T-Cell Engager Therapies
Excalipoint Therapeutics, a Shanghai-based biotechnology company focused on next-generation T-cell engager therapies for cancer and autoimmune diseases, has...
Atavistik Bio Raises USD 40 Million Series B Extension, Totaling USD 160 Million Round
Atavistik Bio Closes USD 40 Million Series B Extension, Bringing Total Round to USD 160 Million
Salspera files to raise USD 85m via Nasdaq IPO for oncology biopharmaceutical platform
Salspera, Inc. (proposed Nasdaq: TKVA), a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company, filed a prospectus for an initial public...
Boehringer Ingelheim licenses preclinical immunometabolic program from Sitryx Therapeutics for over USD 500m
Boehringer Ingelheim (Ingelheim am Rhein, Germany) and Sitryx Therapeutics (Oxford, UK) announced on 26 February 2026 that Boehringer has acquired an...
VST BIO Corporation Closes Series A Financing With $45M Total Investment to Advance Stroke Therapy
VST BIO Corporation, a San Diego-headquartered biotechnology company developing therapeutics for acute ischemic stroke, has closed a Series A financing...
Asahi Kasei Acquires Aicuris Anti-infective Cures for EUR 780m to Bolster Infectious Disease Portfolio
The Asahi Kasei Aicuris acquisition, announced on February 26, 2026, will see the Tokyo-based conglomerate pay approximately EUR 780 million (USD 919...
Samsung Bioepis, Epis NexLab and G2GBIO partner on long-acting semaglutide using microsphere technology
Samsung Bioepis, Epis NexLab, and G2GBIO Enter Research Collaboration and License Agreement for Long-Acting Semaglutide
Vor Bio raises USD 75m in private placement led by TCGX
Vor Bio (Nasdaq: VOR), a Boston-based clinical-stage biotechnology company focused on autoimmune diseases, announced a USD 75 million private placement led...
PRISM BioLab and Receptor.AI collaborate on AI-guided drug discovery targeting protein-protein interactions
PRISM BioLab and Receptor.AI Enter Drug Discovery Collaboration to Target Protein-Protein Interactions with AI-Guided Platform
Tempus AI and Daiichi Sankyo collaborate on AI-driven biomarker discovery for antibody drug conjugate
Tempus AI and Daiichi Sankyo have entered a strategic collaboration to apply artificial intelligence and real-world data analytics to the clinical...
Otsuka Expands Psychiatric Portfolio With USD 1.225b Acquisition of Transcend Therapeutics
Otsuka Pharmaceutical Co., Ltd. has entered into an agreement to fully acquire Transcend Therapeutics, Inc., a clinical-stage biotechnology company...
The AllSci Brief
Systematic R&D and deal news. Daily.